Skip to content

JBIO JBIO Operating Lease Liabilities

Operating Lease Liabilities at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$1.99B+29.2%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
$9.57M-38.6%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$11.49M-15.6%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$0-100%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$1.66M+236%
Vor Biopharma logo
Vor BiopharmaVOR
$2.63M-90.1%

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K
Free cash flow-$33.7M

Valuation

See full
Market cap$1.33B+318%
Enterprise value$1.28B

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity
Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is JBIO's operating lease liabilities?
JBIO (JBIO) reported operating lease liabilities of $679K in Q1 2026.
What is the long-term trend for JBIO's operating lease liabilities?
Over 4 years (2021 to 2025), JBIO's operating lease liabilities has grown at a 17.3% compound annual growth rate (CAGR), from $382K to $724K.
What does operating lease liabilities mean?
Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.